SCDM CCDM Exam With Confidence Using Practice Dumps

The correct and compliant sequence forEDC system setup and implementationbegins onlyafter the study protocol is finalized, as all case report form (CRF) designs, database structures, and validation rules derive directly from the finalized protocol.

According toGCDMP (Chapter: EDC Systems Implementation), the proper order is:

Protocol finalized– defines endpoints and data requirements.

Database created– built according to the protocol and CRFs.

Edit checks created– programmed to validate data entry accuracy.

Database tested (UAT)– ensures functionality, integrity, and compliance.

Sites trained and system released– only then can data entry begin.

Option B follows this logical and regulatory-compliant sequence. Other options (A, C, D) are eitherpaper-based workflowsor violateGCP-compliant timelines(e.g., enrolling subjects before database validation).

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 – System Setup and Implementation Flow

ICH E6(R2) GCP, Section 5.5.3 – Computerized Systems Validation and User Training Before Use

FDA 21 CFR Part 11 – Validation and System Release Requirements

Thebest methodto identify sites withhigh subject attritionis to calculate theproportion of patients for which two visit periods have passed without data, by site.

According to theGCDMP (Chapter: Data Quality Assurance and Control), subject attrition is an important performance indicator for data completeness and site compliance. Evaluating missing or delayed data acrossmultiple consecutive visit periodsallows for early detection of potential dropouts or site-level operational issues.

By assessing this proportion at thesite level, the Data Manager can distinguish between random missing data and systematic site underperformance. Counting or proportioning late visits (options B and C) identifies scheduling delays, not attrition. Looking at missing data without site context (option D) fails to identify site-specific patterns, limiting corrective action.

This metric aligns withrisk-based monitoring (RBM)practices recommended byICH E6 (R2)andFDA RBM Guidance, which promote proactive identification of sites at risk of data loss.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.4 – Site Performance Metrics

ICH E6 (R2) Good Clinical Practice, Section 5.18 – Monitoring and Site Performance Evaluation

FDA Guidance for Industry: Oversight of Clinical Investigations – Risk-Based Monitoring, Section 6 – Site Performance Metrics

If a blood sample is drawndistal (downstream)from a saline infusion site, it may becomecontaminated with saline, leading toabnormal laboratory results. Saline contains a high concentration of sodium chloride, which artificially elevates sodium while diluting other blood components.

Therefore, such samples would display:

Very high sodium levels, and

Abnormally low levelsof other analytes (e.g., proteins, glucose, potassium).

This abnormal pattern (option B) is a classic indicator ofsaline contamination.

Per theGCDMP (Chapter: Data Validation and Cleaning),cross-variable consistency checksare critical for identifying biologically implausible patterns, such as this one, which indicatepre-analytical errorsrather than true physiological changes.

Hence,option Baccurately describes the data signature of a contaminated blood draw.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 – Logical and Consistency Checks for Laboratory Data

ICH E6(R2) GCP, Section 5.1.1 – Data Quality and Biological Plausibility Checks

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 – Detecting Laboratory Anomalies